Skip to content
EN
brief us →

Purdue Pharma L.P.: owners, OxyContin cases and bankruptcy

Purdue Pharma L.P.: participants and roles

Owners, holding partnerships, trustees, directors, officers, affiliates, counterparties, settlement parties and the successor company connected with Purdue Pharma L.P., with the period and source of each role.

published
02 nov 2026
records as of
22 oct 2026
entities
205
sources
115
cite entities.csv
Ad hoc creditor group (governmental and other contingent litigation claimants) in the Chapter 11 cases ofForensic accountant engaged in April 2019 that prepared the cash-transfer (1A) and non-cash-transfer (1B) reports for the Special Committee ofCreditor of (distributor fees, $4,485,373) (+1)Clinical-development contractor (trial design, risk mitigation, NDA materials for Butrans and Hysingla), according to Craig Landau, ofCharity trusteeCharity trusteeDirector (Companies House) and trustee (charity register) of The Sackler TrustFormer partnerClass B DirectorBuyer, through its wholly owned subsidiary Atlantis Consumer Healthcare Inc. and as guarantor, of substantially all the assets of (asset purchase agreement 4 April 2023; $397 million reported; closed 1 June 2023)Arthur Sackler's family (his estate, per a reference work) sold its interest in Purdue to the other two branches, includingBrothersBought the company with his brothers Mortimer and Raymond (a reference work says he arranged the financing and held an option on one third until his estate sold it)Arthur Sackler's family (his estate, per a reference work) sold its interest in Purdue to the other two branches, includingBrothersLicensee of Senokot- and Betadine-branded over-the-counter product rights (licenses to be terminated and the IP assigned to Avrio as a condition of the initial shareholder settlement)Party, with the Debtors, to the Baltimore Stipulation (D.I. 8134) resolving Baltimore's objection to the planPartial owner of (as described in the New York letter rogatory; share not stated)Partial owner of (as described in the New York letter rogatory; share not stated)Owns 50% of the ownership interests of (all Class A shares, per the New York letter rogatory)Valuation and transfer-pricing consultant, retained through the debtors' counsel, that assessed non-cash transfers and Sackler-entity dealings for the Special Committee ofGeneral contractor for the Durham plant ofOwns 50% of the ownership interests ofHeld 259,507 shares, issued in the Kolltan merger and offered for resale, ofIndirectly owns, in equal parts with Rosebay, 99.5% of (through BR Holdings Associates L.P. and PLP Associates Holdings L.P.)Trustee of the Beacon Trust, which is the general partner ofEstate of Beverly Sackler listed as a payment party of both B-Side Payment GroupsDirector of Napp Pharmaceutical Group Limited (UK IAC)DirectorBeneficiary of Trust U/A 11/5/74 (the "74A Trust", trustee Cedar Cliff Fiduciary Management Inc. in 2020), an RRS Family trust indirectly owningDirector of the UK Raymond and Beverly Sackler Foundation (06802985)Mother ofGeneral partner of (as described in the New York letter rogatory)Owns 100% of the ownership interests ofDirector of Napp Pharmaceutical Group Limited (UK IAC)Creditor of (distributor fees, $3,468,979) (+1)Director of MNP Consulting Limited (Delaware IAC)Director of Mundipharma Verwaltungsgesellschaft mbH (German IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director (Class A Director)Owns 100% of (merger completed 29 November 2016; Kolltan investors received 18,257,996 Celldex shares)Director of the trustee of the Beacon Trust (general partner of Beacon Company)Director of the trustee of the Beacon Trust (general partner of Beacon Company)Director of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director of The Sackler TrustDirector of TRADEWHIZ LIMITEDCorporate company secretaryUses the firm's New York office as its care-of address for SEC noticesOwns 100% of the ownership interests of, as trustee under a Trust Agreement of 23 December 1989Alleged owner of (New York, September 2019: 100%; Rhode Island, 2022: sole limited partner holding its interests)Alleged 100% owner of, according to the New York Attorney GeneralPresident and Chief Executive OfficerPresident and Chief Executive OfficerPresident and Chief Executive Officer (+1)Oversees the generic medicine business (Rhodes Pharma)Movant against, in the motion to enforce the Confirmation Order and the Stipulation (ECF No. 9189), granted in fullMovant against, in the motion to enforce the Confirmation Order and the Stipulation (ECF No. 9189), granted in fullOwns 100% of the ownership interests of, as trustee under a Trust Agreement of 23 December 1989Recorded as shareholder in leaked offshore-registry dataListed as a payment party of B-Side Payment Group 1Director of the IAC advisory board MNP/MNCDirector of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)DirectorBeneficiary of trusts that indirectly ownMember of the Board of TrusteesCounsel (attorneys for the non-party) toCounsel (attorneys for the non-party) toCounsel (attorneys for the non-party) toCounsel (attorneys for the non-party) toCounsel (attorneys for the non-party) toCreditor of (trade debt; amount not legible)VP, FinanceExecutive vice president (undated listing)Movant against, in the motion to enforce the Confirmation Order and the Stipulation (ECF No. 9189), granted in fullMovant against, in the motion to enforce the Confirmation Order and the Stipulation (ECF No. 9189), granted in fullOwns 100% of the ownership interests of, as trustee under a Settlement dated 31 December 1993Recorded as shareholder in leaked offshore-registry dataGeneral Counsel from 1977; Group Vice President and General Counsel (1989), Executive Vice President and General Counsel (1999), Executive Vice President and Chief Legal Officer (2003); a responsible corporate officer for 1996 to 30 June 2001Settlement obligor: third-tier obligor of A-Side Payment Group 3Director of the IAC advisory board MNP/MNCCharity trustee, listed as "Mrs I Sackler Lefcourt"Director of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director (first term) (+1)Vice PresidentSenior Vice President, Licensing and Business DevelopmentOfficer; signed for the company as Vice PresidentAttorney atDirector of the trustee of the Beacon Trust (general partner of Beacon Company)Director (with voting and investment control over Beacon Company's securities)Chairman of the Special Committee of the board (+1)Chief Executive OfficerChief Executive Officer (+1)VP, Chief Financial Officer (signing for PPI as general partner)Senior Vice President and Chief Financial Officer (acting CFO from August 2017) (+1)Estate of Jonathan D. Sackler listed as a payment party of B-Side Payment Group 2Director of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director (+1)Beneficiary of trusts that indirectly own (the agreement was signed by his estate) (+1)Director of the UK Raymond and Beverly Sackler Foundation (06802985)Brothers (the two sons of Raymond Sackler)Director of the general partner of Rosebay Medical Company L.P., with voting and investment control over its securitiesCo-trustee, with Richard S. Sackler, under a Trust Agreement of 5 November 1974 owning 98% ofDirector of the trustee of the Beacon Trust (general partner of Beacon Company)Director (with voting and investment control over Beacon Company's securities)Director of Napp Pharmaceutical Holdings Limited (UK IAC), recorded as "Judy Lewent"Director (non-family)Member of the board of directorsSettlement obligor: third-tier obligor of A-Side Payment Group 2Director of the IAC advisory board MNP/MNCCharity trusteeDirector of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director (+1)Beneficiary of trusts that indirectly own (+1)Construction contractor for the Durham, North Carolina oral solid dosage plant (and earlier construction services), according to KBR, ofMember of the Special Committee of the board (+1)Owns 100% of (sole owner; nonprofit 501(c)(4) foundation that oversees the company)Successor to the business and substantially all operating assets of (NewCo under the confirmed plan)Single-family office providing investment management to the trust of which Cornice is trusteeSingle-family office providing investment management toDirector of the trustee of the Beacon Trust (general partner of Beacon Company)Officer (he had been trustee of the trust for the issue of Jonathan D. Sackler until Cornice succeeded him on 20 November 2018)Attorney atBrought (with Richard Sackler) a new civil action against, noticed by a lis pendens on property of a pledged Side B trust; held by the Bankruptcy Court to breach the settlementPetitioner (with Richard Sackler) in a Wyoming state-court petition seeking an accounting and income distributions from four pledged trusts of which Data LLC is trustee; held by the Bankruptcy Court to breach the settlementOwns 25% of the ownership interests ofThird-party manufacturer of Butrans forInterim President and Chief Executive Officer (pending a search for a permanent CEO)Senior Vice President, General Counsel and SecretarySenior Vice President and General Counsel; later Executive Vice President, General Counsel and Chief Legal OfficerGeneral manager (as reported)Chief medical officer (as reported)General Counsel (head of the law department)Held a public-relations ("PR") role; terms of engagement not statedConsultant in the research and development department on OxyContin projects (never an officer or director)Chief Executive OfficerPresident and Chief Executive Officer (+1)Former senior partner ofDirector of McKinsey's client services team for about 30 engagements withJoined the Side B Trustees' motion to enforce the Confirmation Order against (fees and costs awardable on application)Receives the majority of the estates' value, including the Estate Claims Settlement proceeds, for distribution to the creditor trustsJoined the Side B Trustees' motion to enforce the Confirmation Order against (fees and costs awardable on application)Program manager for the Durham plant ofCreditor of (distributor fees, $3,655,581) (+1)Parent company of (U.S. subsidiary)Management consultant to (75 U.S. engagements)Consultant to (U.S. subsidiary whose consultants worked on Purdue projects)Member of the Special Committee of the board (+1)President and Chief Executive Officer; pleaded guilty in that capacity in May 2007 and was described by HHS-OIG in 2009 as a former executive (+1)Described as chief executive officer (alleged)Described as chief executive officer (alleged)Member of the board of directors (audit chair)Owns 100% of the ownership interests of, as trustee of the Hercules Trust (Declaration of Trust of 2 March 1999)Father ofFather ofFather ofDirector of Napp Pharmaceutical Group Limited (UK IAC)Bought the company with his brothers Arthur and RaymondCo-chairman, with Raymond Sackler (per a reference work)Co-chief executive officer (with Raymond Sackler)Brothers (co-chief executive officers of Purdue)Director of The Sackler TrustFather of (per a reference biography)SpousesDirector of TRADEWHIZ LIMITEDSettlement obligor: third-tier obligor of A-Side Payment Group 4Director of the IAC advisory board MNP/MNCCharity trusteeDirector of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director (+1)Beneficiary of trusts that indirectly own (+1)Family for whose benefit Banela holds all Class A shares of Purdue Pharma Inc. (per the New York letter rogatory)Side A family; Beacon, its partnership in the chain, is owned by trusts established for the benefit of the Sackler familiesAd hoc creditor group of 1,317 local governmental and other entities (Multi-State Governmental Entities Group) in the Chapter 11 cases ofStrategic alliance partner (commercialization rights outside the United States) ofChair of the board of directorsCare-of address (Oklahoma City) given for Rosebay Medical Company L.P.Legal counsel to the Debtors (also listed as counsel to Shareholder Released Parties)Provided facilities and administrative servicesProvided facilities and administrative services (and was counterparty to the headquarters lease)Member of the board of directors (HR and compensation chair)Chair of the Board of TrusteesMedical Director (1985), later scientific and medical affairs posts, Executive Vice President of Worldwide Research & Development (2000) and Chief Scientific Officer (2003); a responsible corporate officer for 1996 to 30 June 2001Director of Napp Pharmaceutical Holdings Limited (UK IAC), recorded as "Paulo Ferraz Costa"Director (non-family)Owns 25% of the ownership interests ofDirector of Napp Pharmaceutical Holdings Limited (UK IAC)Director (non-family)Board member (alleged)Manufactured, at Totowa, New Jersey, the OxyContin tablets sold and distributed by, according to the 2020 InformationBoard member (the board holds the power to vote and dispose of Beacon Company's securities)Administers the wind-up of the Debtors' estates under the plan (files hearing agendas in the case; its trustee pays the PPLP Liquidator from the Wind-Up Reserve)General partner of (as described in the New York letter rogatory; the New York complaint calls it a partner)Owns approximately 99.5061% of the ownership interests of (holder of the remainder not stated)Owns 100% of the ownership interests (the whole limited partnership interest) ofAdvertising agency forIndependent associated company under the same ultimate owners as, but not a subsidiary or a debtor with,Co-owner, with Purdue Pharma L.P., of the general partnership (which conducted pharmaceutical business and recorded OxyContin sales from about January 1996)Became an owner of (share not stated) after The Purdue Pharma Company was terminatedDistributed profits, including OxyContin proceeds, by wire transfer (about $2,854,760,301 in total with Purdue Pharma L.P.) to, according to an IRS agentDistributed profits, including OxyContin proceeds, by wire transfer (about $2,854,760,301 in total with The Purdue Frederick Company) to, according to an IRS agentGeneral partner of, according to the Rhode Island Attorney GeneralGeneral partner of Purdue Holdings L.P., now PRA (as alleged by the State of Connecticut)Entirely controlled The Purdue Frederick Company, which went out of business in 2007 (allegation of the Connecticut Attorney General)General partner of (replaced non-debtor general partners before the petition date) (+1)General partner of (its board of directors manages the partnership)Connected corporation, by the committee's registered name (corporation PAC registered 17 December 2001; now terminated), ofGeneral partner of (replaced non-debtor general partners before the petition date)General partner ofOwns 100% ofResearch collaborator on non-opioid, non-NSAID chronic-pain compounds, announced between 2014 and June 2017, withWith The P.F. Laboratories and Purdue Pharmaceuticals, agreed to pay $30 million on signing and $32 million by 1 February 2019 (royalty settlement and dismissal of Depomed v. Purdue, D.N.J. 3:13-cv-00571) toOwns 100% ofPaid distributions, directly and through PLP and BR holding companies, to (Side A partnership; e.g. $100 million on 6 November 2008 per the United States; 2008–2011 amounts alleged by Connecticut); transferred Novelos securities in 2009 toPaid cash distributions to (United States: December 2011 – September 2017, the last $200,000; Connecticut: conduit for 2010–2011 distributions to Rosebay and Beacon)Held an equity interest in (valued at $52,328,000 in Purdue's records when transferred to PRA LP, estimated date 1 January 2008), according to the United StatesCo-development and commercialization partner for lemborexant ofWith the other Purdue Companies, asserted OxyContin patent infringement (S.D.N.Y. actions 00 Civ. 8029, 01 Civ. 2109, 01 Civ. 8177 over ANDA No. 75-923) against; settled 28 August 2006 with a consent judgment, patent licence and mutual releasesWith the other Purdue Companies, litigated OxyContin patent claims against and settled them on 28 August 2006 withParty to a $790 million strategic research collaboration on psoriasis treatments withOwns 100% ofOwns 100% ofInvestor in (according to Richard Sackler, an investment that ended in approximately 2013; the United States lists Infinity stock transferred to PRA LP in 2008, 2009 and 2013)Held stock in (valued at $12,950,000 when transferred to PRA LP on 30 September 2009; further stock and cash of $2,170,802 on 31 December 2014), according to the United StatesHeld equity in (recorded at negative $543,000 when transferred to PRA LP in 2010), according to the United StatesHeld equity in (valued at $7,412,000 when transferred to PRA LP on 1 January 2009), according to the United StatesOwns 100% ofHeld equity in (valued at $32,761,081 when transferred to PRA LP in 2010), according to the United StatesBought 200 Series E preferred shares and warrants for $10,000,000 on 11 February 2009, then transferred its Novelos securities to Beacon Company and Rosebay Medical Company L.P., ofOwns 100% ofPaid smaller cash distributions (e.g. $492,818 on 25 September 2008) to, according to the United StatesPaid cash distributions to (United States: e.g. $50 million, $250 million and $199 million in 2008; Connecticut: conduit for 2010–2011 distributions to Rosebay and Beacon)Lent $313 million to its parent (repaid before the September 2019 petition date)Paid cash distributions to its parent (as Purdue Holdings L.P., September 2010 – September 2011, e.g. $261,290,537 on 2 December 2010) and transferred non-cash assets valued in Purdue's records at a stated $412,272,152 (equity stakes, Infinity, Kolltan and Novelos stock, product rights) to, according to the United StatesPaid Practice Fusion, an electronic health records vendor, in exchange for referring, recommending and arranging for the ordering of OxyContin, Butrans and Hysingla through a sponsored 'Pain CDS' alert, conduct admitted in the 2020 plea (Count Three); the Information puts the contract in about March 2016 and the payments at about $959,700 from March to November 2016, and alleges the alert ran from July 2016 to about April 2019Alternative obligor for the financial obligations of Purdue Frederick's 2007 plea agreement, which defines the paying party as either company, including at least $5,012,722.40 of monitoring costs over 72 months for Purdue Pharma L.P.'s own Corporate Integrity Agreement; HHS-OIG described the two companies as agreeing together to pay $600 millionOwns 99% ofCo-owner, with The Purdue Frederick Company, Inc., of the general partnership (+1)Paid smaller cash distributions (e.g. $495,000 on 25 September 2008) to its general partner, according to the United StatesOwns 100% ofOwns 100% ofOwns 100% ofOwns 100% ofOwns 100% of (head of the Rhodes generic-medication debtors)Parent of Rhodes Tech (or its predecessor) until it was moved to another Sackler ownership chain on or around 1 January 2008; indirect owner again through Rhodes Associates L.P. from May 2019Parent of (Rhodes Technologies Inc. described as its subsidiary), according to the Rhode Island Attorney GeneralPaid distributions, directly and through PLP and BR holding companies, to (Side B partnership; e.g. $100 million on 6 November 2008 per the United States; 2008–2011 amounts alleged by Connecticut); transferred Novelos securities in 2009 toPaid cash distributions, including tax distributions, and transferred non-cash assets to or for the benefit of (1A Report: about $10.347 billion net cash with Rhodes, January 2008 – September 2019; debtors' acknowledgement: $1.322 billion in 1995–2007, of which $1.192 billion for taxes)Owns 100% ofAlliance partner for the U.S. launch and commercialization of Symproic (naldemedine) ofAcquired the non-opioid treatment VM-902A and the TrkA pain program from, according to a company announcementGeneral partner ofStrategic alliance partner (development and commercialization of FAAH products in the United States, with equity and credit commitments announced by "Purdue") ofCreditor of (trade debt, $150,000)Member of the Board of TrusteesDirector of Napp Pharmaceutical Holdings Limited (UK IAC)Director (non-family)SpousesFather ofDirector of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Bought the company with his brothers Arthur and MortimerCo-chairman, with Mortimer Sackler (per a reference work)Listed as directorCo-chief executive officer (with Mortimer D. Sackler)Father ofOwns, directly or indirectly through family persons or trusts (RRS Family I-way entity)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity in the Purdue Pharma L.P. ownership chain)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity in the Purdue Pharma L.P. ownership chain)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity in the Purdue Pharma L.P. ownership chain)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity in the Purdue Pharma L.P. ownership chain)Side B family; Rosebay, its partnership in the chain, is owned by trusts established for the benefit of the Sackler families (an RRS Family I-way entity in Exhibit X)Owns, directly or indirectly through family persons or trusts (RRS Family I-way entity in the Purdue Pharma L.P. ownership chain)Owns 100% ofOwns 100% ofOwns 100% ofGeneral partner of, according to state complaintsSold its Coventry, Rhode Island active-pharmaceutical-ingredient plant and related assets (agreement 14 September 2020, court approval 1 October 2020, closing 31 December 2020; about 120 employees affected) toOwns 100% ofOwns 100% ofUnsecured creditor (services fees, listed among the 50 largest unsecured claims) ofGeneral partner (managing general partner per New York) of, according to state complaintsOwns the equity of (his Personal Limited Liability Company under Annex G; 100% of the equity pledged to the MDT)Brought (with Lin Gao) a new civil action against, noticed by a lis pendens on property of a pledged Side B trust; held by the Bankruptcy Court to breach the settlementPetitioner (with Lin Gao) in a Wyoming state-court petition seeking an accounting and income distributions from four pledged trusts of which Data LLC is trustee; held by the Bankruptcy Court to breach the settlementFather ofSpousesCo-trustee of a family trust of 15 January 2004, which wholly ownsFather ofSettlement obligor and individual pledgor under Annex G (credit support for the Richard Sackler family Payment Group, B-Side Payment Group 1; "naked pledge" in favour of the MDT)Director of the IAC advisory board MNP/MNCDirector of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Chair of the board (+2)Beneficiary of trusts that indirectly own (+1)Described as former chief executive officerBoard member (alleged)Director of the general partner of Rosebay Medical Company L.P., with voting and investment control over its securitiesCo-trustee, with Jonathan D. Sackler, under a Trust Agreement of 5 November 1974 owning 98% ofDirector (signature block of the 2007 plea documents: "Vice-President and Director") (+1)Vice president (undated listing)Vice-President and Associate General CounselCreditor of (claim listed for its successor, the RDC Liquidating Trust)Movant against, in the motion to enforce the Confirmation Order and the Stipulation (ECF No. 9189), granted in fullMovant against, in the motion to enforce the Confirmation Order and the Stipulation (ECF No. 9189), granted in fullListed as a payment party of both B-Side Payment GroupsGeneral partner of (its board holds the power to vote and dispose of the partnership's securities)Recorded as shareholder in leaked offshore-registry dataOwns 50% of the ownership interests ofHeld 259,507 shares, issued in the Kolltan merger and offered for resale, ofOne of four registered owners of Mundipharma's Italian branch (with three Luxembourg companies), per the Italian business register as reportedIndirectly owns, in equal parts with Beacon, 99.5% of (through BR Holdings Associates L.P. and PLP Associates Holdings L.P.)Vice President of Sales and Marketing (as alleged)Owes, through its payment parties, up to about $7 billion over fifteen years (plus up to $500 million contingent on IAC sales) under the Master Shareholder Settlement AgreementOwns and controls (together with the PLP Associates Holdings and BR Holdings Associates entities), as asserted by the United StatesUltimate owners, through the same entities that own the debtors (Purdue Canada is an independent associated company the Sackler Parties undertook to sell), ofFamily members who served as directors or officers are indemnitees (expenses, settlements, judgments and advanced defence costs; no indemnity where a final decision finds bad faith) under the 2004 Sackler-Purdue Indemnity Agreement and the limited partnership agreements of (+4)Owned (through trusts) and controlled, as alleged by the United States in Addendum A to the 2020 settlementSettlement obligor: third-tier obligor of A-Side Payment Group 8 (the group's $345 million obligation is prepayable at its agreed present value)Charity trustee, listed as "Samantha Sophia Hunt"Director of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)Lead design firm and civil, structural and MEP engineer for the Durham plant ofManaging general partner of (its board holds the power to vote and dispose of Beacon's securities)Appellant, with seven other states and the District of Columbia, from the 2021 confirmation order (withdrew its opposition under the term sheet approved on 10 March 2022) against (+2)Plaintiff (consumer-protection claim against seven family members) againstVice President (signed for Kokino as managing member of Piton Capital Management LLC)Vice President (signatory of its SEC filings)Director and/or officer, sharing voting and investment control over Rosebay Medical Company L.P.'s securitiesDirector of Napp Pharmaceutical Group Limited (UK IAC)Chairman of the Board (+1)Director (with voting and investment control over Beacon Company's securities)Director of the trustee of the Beacon Trust (general partner of Beacon Company)Director of MUNDIPHARMA IT SERVICES LIMITED (07485493)Director of MUNDIPHARMA LIMITED (00553824)Director of Napp Pharmaceutical Group Limited (UK IAC), recorded as "Stuart David Baker"Director of Napp Pharmaceutical Holdings Limited (UK IAC)Director of PAINEUROPE LIMITED (02714090)Executive Vice President, Counsel to the Board and SecretaryCreditor of (trade debt, $1,073,469)Treasurer and Chief Financial OfficerBeneficiary of the Hercules Trust, which (through its trustee Millborne) owns 100% ofNamed among the beneficiaries ("F.B.O. the issue of Mortimer D. Sackler M.D., Theresa E. Sackler and certain charitable objects") of the 1993 Settlement that ownsDirector of FORMULATION PRODUCTS LIMITEDSettlement obligor: third-tier obligor of A-Side Payment Group 1 and fourth-tier obligor of A-Side Payment Groups 5 to 7Director of the IAC advisory board MNP/MNCDirector (Companies House) and trustee (charity register) of The Dr. Mortimer and Theresa Sackler FoundationDirector of Napp Pharmaceutical Group Limited (UK IAC)Director of Napp Pharmaceutical Holdings Limited (UK IAC)DirectorDirector of The Sackler Trust (07022224)Director of TRADEWHIZ LIMITEDCorporate company secretaryCorporate company secretaryCorporate company secretaryCorporate company secretaryCorporate company secretaryCorporate company secretary (+1)Corporate company secretary (+1)Corporate company secretaryCorporate company secretaryCorporate company secretaryCorporate company secretaryProvided accounting and other administrative servicesProvided accounting and other administrative servicesOfficial Committee of Unsecured Creditors in the Chapter 11 cases (mediation party, party to the UCC Stipulation; sole standing to prosecute the estates' causes of action from November 2024) ofAs U.S. Trustee, Region 2, opponent of the plan's nonconsensual releases: appellant in the District Court (2021), appellee in the Second Circuit (2022-2023) and petitioner in the Supreme Court (Harrington v. Purdue Pharma L.P., No. 23-124) againstKolltanPharmaceuticalsKolltan PharmaceuticalsPaulo CostaA31Paulo CostaA31: Named as a director defendant in the Massachusetts and Connecticut suits (2019)Judith C. LewentA34Judith C. LewentA34: Named as a director defendant in the Massachusetts and Connecticut suits (2019)MNP/MNC advisoryboardMNP/MNC advisory boardIlene SacklerLefcourtA19Ilene Sackler LefcourtA19: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimantsSamantha SophiaSackler HuntSamantha Sophia Sackler HuntThe Dr. Mortimerand TheresaSackler FoundationThe Dr. Mortimer and Theresa Sackler FoundationTheresa E. SacklerA21Theresa E. SacklerA21: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimantsChristopher BenbowMitchellChristopher Benbow MitchellTradewhiz LimitedTradewhiz LimitedThe Sackler TrustThe Sackler TrustAnthony CollinsAnthony CollinsCornhill ServicesLimitedCornhill Services LimitedStephen JohanJamiesonStephen Johan JamiesonHoward R. UdellA10 · A11Howard R. UdellA10: Pleaded guilty in May 2007 to misdemeanor misbranding as a responsible corporate officer · A11: Excluded from federal health care programs by HHS-OIG; upheld by an administrative law judge in 2009BE&K BuildingGroupBE&K Building GroupCelldexTherapeutics, Inc.Celldex Therapeutics, Inc.Ralph SnydermanA33Ralph SnydermanA33: Named as a director defendant in the Massachusetts and Connecticut suits (2019)David A. SacklerA18 · A27David A. SacklerA18: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants · A27: Party to the October 2020 civil settlement with the United States ($225 million), without admission of liabilityMortimer D.A.SacklerA16 · A25Mortimer D.A. SacklerA16: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants · A25: Party to the October 2020 civil settlement with the United States ($225 million), without admission of liabilityKathe A. SacklerA17 · A26Kathe A. SacklerA17: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants · A26: Party to the October 2020 civil settlement with the United States ($225 million), without admission of liabilityNappPharmaceuticalHoldings LimitedNapp Pharmaceutical Holdings LimitedNappPharmaceuticalGroup LimitedNapp Pharmaceutical Group LimitedMortimer D.SacklerMortimer D. SacklerPainEurope LimitedPainEurope LimitedTiercel ServicesLimitedTiercel Services LimitedFormulationProducts LimitedFormulation Products LimitedPaul D. GoldenheimA12 · A13Paul D. GoldenheimA12: Pleaded guilty in May 2007 to misdemeanor misbranding as a responsible corporate officer · A13: Excluded from federal health care programs by HHS-OIG; upheld by an administrative law judge in 2009Mundipharma ITServices LimitedMundipharma IT Services LimitedMundipharmaInternationalLimitedMundipharma International LimitedBardPharmaceuticalsLimitedBard Pharmaceuticals LimitedBryan George LeaBryan George LeaNorth BayAssociatesNorth Bay AssociatesRosebay MedicalCompany L.P.A40Rosebay Medical Company L.P.A40: Named as a defendant in the State of New York's opioid suit (2019)Rosebay MedicalCompany, Inc.Rosebay Medical Company, Inc.Purdue MasterDisbursement TrustPurdue Master Disbursement TrustJonathan D.SacklerA15 · A24Jonathan D. SacklerA15: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants · A24: Party to the October 2020 civil settlement with the United States ($225 million), without admission of liabilityRaymond R. SacklerRaymond R. SacklerArthur SacklerArthur SacklerThe PurdueFrederick Company,Inc.A6 · A7The Purdue Frederick Company, Inc.A6: Pleaded guilty in May 2007 to felony misbranding of OxyContin · A7: Excluded from federal health care programs for 25 years from 2007 (HHS-OIG)Stuart D. BakerStuart D. BakerRaymond andBeverly SacklerFoundationRaymond and Beverly Sackler FoundationMundipharmaLimitedMundipharma LimitedMcKinsey &Company, Inc.United StatesA54 · A55McKinsey & Company, Inc. United StatesA54: Charged by Information in December 2024; resolved by a deferred prosecution agreement · A55: Defendant in New York's February 2021 complaint, filed with a consent judgmentMundipharma ItalyA58Mundipharma ItalyA58: Italian branch reported fined in a 2019 corruption case; the company denied wrongdoingMarcelo BigalMarcelo BigalSSOE Inc.SSOE Inc.McKee BuildingGroupMcKee Building GroupMcKessonCorporationA44McKesson CorporationA44: Named in its own capacity as a distributor defendant in state opioid suitsBR HoldingsAssociates L.P.BR Holdings Associates L.P.Mark TimneyA36Mark TimneyA36: Named as a former-CEO defendant in the Massachusetts and Connecticut suits (2019)State of MarylandState of MarylandRichard S. SacklerA14 · A23 · A28Richard S. SacklerA14: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants · A23: Party to the October 2020 civil settlement with the United States ($225 million), without admission of liability · A28: Found by the Bankruptcy Court in 2026 to have breached the 2025 settlement and confirmation orderBeverly SacklerA20Beverly SacklerA20: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimantsRobin E. AbramsRobin E. AbramsMichael FriedmanA8 · A9Michael FriedmanA8: Pleaded guilty in May 2007 to misdemeanor misbranding as a responsible corporate officer · A9: Excluded from federal health care programs by HHS-OIG; upheld by an administrative law judge in 2009Beacon TrustCompany Ltd.Beacon Trust Company Ltd.Marianna SacklerA22Marianna SacklerA22: Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimantsLeslie J. SchreyerLeslie J. SchreyerMcKinsey &Company, Inc.A52 · A53McKinsey & Company, Inc.A52: Agreed in December 2024 to pay $650 million to resolve federal criminal and civil investigations of its Purdue work · A53: February 2021 consent judgment with 47 states and others resolving investigations of its opioid workMartin E. EllingA56Martin E. EllingA56: Charged in December 2024 with destroying records, according to the Justice DepartmentAdlon TherapeuticsL.P.Adlon Therapeutics L.P.Purdue PharmaManufacturing L.P.Purdue Pharma Manufacturing L.P.KBR Building GroupKBR Building GroupCardinal Health,Inc.A45Cardinal Health, Inc.A45: Named in its own capacity as a distributor defendant in state opioid suitsPLP AssociatesHoldings L.P.A42PLP Associates Holdings L.P.A42: Named as a defendant in the State of New York's opioid suit (2019)PharmaceuticalResearchAssociates L.P.A39Pharmaceutical Research Associates L.P.A39: Named as a defendant in the State of New York's opioid suit (2019)Sackler familySackler familyPurdue Pharma L.P.A1 · A2 · A3 · A4Purdue Pharma L.P.A1: Pleaded guilty in November 2020 to three federal conspiracy counts; sentenced in April 2026 · A2: Defendant in opioid suits by states and others; claims resolved through settlements and the 2025 bankruptcy plan · A3: Entered 2007 consent judgments with 26 states and D.C. over OxyContin promotion · A4: Filed for Chapter 11 on 15 September 2019; reorganisation plan effective 1 May 2026Jon LowneJon LowneBeacon CompanyA41Beacon CompanyA41: Named as a defendant in the State of New York's opioid suit (2019)The Purdue PharmaCompanyThe Purdue Pharma CompanyPurduePharmaceuticalProducts L.P.Purdue Pharmaceutical Products L.P.InfinityPharmaceuticals,Inc.Infinity Pharmaceuticals, Inc.RhodesTechnologies Inc.A51Rhodes Technologies Inc.A51: Named as a defendant in the State of Rhode Island's opioid suit (complaint as amended in 2022)Norton RoseFulbright US LLPNorton Rose Fulbright US LLPMulti-StateGovernmentalEntities GroupMulti-State Governmental Entities GroupPurdue TransdermalTechnologies L.P.Purdue Transdermal Technologies L.P.Analgesic ResearchAnalgesic ResearchImbriumTherapeutics L.P.Imbrium Therapeutics L.P.BR HoldingsAssociates, Inc.BR Holdings Associates, Inc.PLP AssociatesHoldings, Inc.PLP Associates Holdings, Inc.John S. DubelJohn S. DubelJohn StewartA35John StewartA35: Named as a former-CEO defendant in the Massachusetts and Connecticut suits (2019)Purdue Pharma Inc.A5Purdue Pharma Inc.A5: Named with Purdue Pharma L.P. as a defendant in state opioid suits (2018–2019)Banela CorporationBanela CorporationThe Mortimer D.Sackler Family(Side A)The Mortimer D. Sackler Family (Side A)Millborne TrustCompany LimitedMillborne Trust Company LimitedPerthlite HoldingsLLCPerthlite Holdings LLCF. Peter BoerA30F. Peter BoerA30: Named as a director defendant in the Massachusetts and Connecticut suits (2019)Cornice FiduciaryManagement LLCCornice Fiduciary Management LLCAnthony M.RoncalliAnthony M. RoncalliJeffrey RobinsJeffrey RobinsPurdue Pharma Inc.Political ActionCommitteePurdue Pharma Inc. Political Action CommitteeExicureExicureShionogiShionogiM3C Holdings LLCM3C Holdings LLCKokino LLCKokino LLCRaymond Sacklerfamily (Side B)Raymond Sackler family (Side B)Robert S. (Steve)MillerRobert S. (Steve) MillerPurdueNeuroscienceCompanyPurdue Neuroscience CompanyPurdue Pharma(Canada)Purdue Pharma (Canada)ARIT InvestmentHoldings LLCARIT Investment Holdings LLCHeatheridge TrustCompany LimitedHeatheridge Trust Company LimitedEdward B. MahonyEdward B. MahonyCoventryTechnologies, L.P.Coventry Technologies, L.P.RhodesTechnologiesA50Rhodes TechnologiesA50: Named as a defendant in the State of Rhode Island's opioid suit (complaint as amended in 2022)Noramco CoventryLLCNoramco Coventry LLCUDF L.P.UDF L.P.SVC Pharma Inc.SVC Pharma Inc.AnaBiosAnaBiosMaria BartonMaria BartonAvrio Health L.P.Avrio Health L.P.Stephen A. IvesStephen A. IvesLinarite HoldingsLLCLinarite Holdings LLCData LLCData LLCKenneth A.BuckfireKenneth A. BuckfireCraig LandauA37Craig LandauA37: Named as a defendant in the Massachusetts suit and in other suits reported in 2019Lin GaoA29Lin GaoA29: Found by the Bankruptcy Court in 2026 to have breached the 2025 settlement and confirmation orderDebevoise &Plimpton LLPDebevoise & Plimpton LLPFrank S. VellucciFrank S. VellucciRhodesPharmaceuticalsL.P.A49Rhodes Pharmaceuticals L.P.A49: Named as a defendant in the State of Rhode Island's opioid suit (complaint as amended in 2022)Rhodes AssociatesL.P.Rhodes Associates L.P.Paul Land Inc.Paul Land Inc.EisaiEisaiLucien HoldingsS.ar.l.Lucien Holdings S.ar.l.NovelosTherapeutics, Inc.Novelos Therapeutics, Inc.Nayatt CoveLifescience Inc.Nayatt Cove Lifescience Inc.Arcadia ConsumerHealthcare Inc.Arcadia Consumer Healthcare Inc.MundipharmaVerwaltungsgesellschaft mbHMundipharma Verwaltungsgesellschaft mbHCecil B. PickettA32Cecil B. PickettA32: Named as a director defendant in the Massachusetts and Connecticut suits (2019)One StamfordRealty L.P.One Stamford Realty L.P.PurduePharmaceuticalsL.P.Purdue Pharmaceuticals L.P.Michael ColaMichael ColaRory HeldRory HeldJonathan G. WhiteJonathan G. WhiteThe P.F.Laboratories, Inc.A43The P.F. Laboratories, Inc.A43: Named as a defendant in the State of New York's opioid suit (2019)RhodesPharmaceuticalsInc.Rhodes Pharmaceuticals Inc.DezenhallResourcesDezenhall ResourcesOfficial Committeeof UnsecuredCreditors ofPurdue PharmaL.P., et al.Official Committee of Unsecured Creditors of Purdue Pharma L.P., et al.Rochester DrugCooperative Inc.A47Rochester Drug Cooperative Inc.A47: Named in its own capacity as a distributor defendant in state opioid suitsPublicis Health,LLCA57Publicis Health, LLCA57: $350 million agreement with state attorneys general in 2024 over its opioid marketing workWilliam K.HarringtonWilliam K. Harrington"Sackler -Mortimer D."(offshore leaksrecord)"Sackler - Mortimer D." (offshore leaks record)New SuffolkHoldings LLPNew Suffolk Holdings LLPCedar CliffFiduciaryManagement Inc.Cedar Cliff Fiduciary Management Inc.Roselite HoldingsLLCRoselite Holdings LLCOphir Green Corp.Ophir Green Corp.TXP Services Inc.TXP Services Inc.AmerisourceBergenA48AmerisourceBergenA48: Listed in 2024 by the New York Attorney General among companies paying opioid recoveriesDaniel S. ConnollyDaniel S. ConnollyStanhope GateCorp.Stanhope Gate Corp.Joerg FischerJoerg FischerPurduePharmaceuticalProducts Inc.Purdue Pharmaceutical Products Inc.MundipharmaInternationalCorporationLimitedMundipharma International Corporation LimitedPhilip J. Le CornuPhilip J. Le CornuSheldrake LimitedSheldrake LimitedRosebay MedicalCompany LLCRosebay Medical Company LLCHillside TrustCompany LimitedHillside Trust Company LimitedMerganser LimitedMerganser LimitedMoonstone HoldingsLLCMoonstone Holdings LLCABSG LLCABSG LLCEndoPharmaceuticalsInc.Endo Pharmaceuticals Inc.GreenfieldBioVentures L.P.Greenfield BioVentures L.P.Bates White LLCBates White LLCMarc L. KesselmanMarc L. KesselmanKnoa Pharma LLCKnoa Pharma LLCSteven MeiklejohnSteven MeiklejohnPatricia LangPatricia LangJames J. DolanJames J. DolanKnoa FoundationKnoa FoundationDavid SaltzmanDavid SaltzmanRahul GuptaRahul GuptaButton Land L.P.Button Land L.P.Quidnick Land L.P.Quidnick Land L.P.Mundipharma GroupMundipharma GroupMillsaw RealtyL.P.Millsaw Realty L.P.Syneos HealthSyneos HealthMNP ConsultingLimitedMNP Consulting LimitedEndoPharmaceuticalsHoldings Inc.Endo Pharmaceuticals Holdings Inc.AlixPartners LLPAlixPartners LLPAd Hoc Committeeof Governmentaland OtherContingentLitigationClaimantsAd Hoc Committee of Governmental and Other Contingent Litigation ClaimantsMike McHaleMike McHaleNorbert RiedelNorbert RiedelCharles G. LubarCharles G. LubarPractice Fusion,Inc.Practice Fusion, Inc.Paul B. RothmanPaul B. RothmanPhilip C.StrassburgerPhilip C. StrassburgerPurdue Pharma ofPuerto RicoPurdue Pharma of Puerto RicoMortimer-sideInitial CoveredSackler PersonsMortimer-side Initial Covered Sackler PersonsEuro-Celtique S.A.Euro-Celtique S.A.AmerisourceBergenDrug CorporationA46AmerisourceBergen Drug CorporationA46: Named in its own capacity as a distributor defendant in state opioid suitsAssertioTherapeutics, Inc.Assertio Therapeutics, Inc.Russell J. GasdiaA38Russell J. GasdiaA38: Named as a defendant in the Massachusetts suit (2019)The PlanAdministrationTrustThe Plan Administration TrustSeven Seas HillCorp.Seven Seas Hill Corp.Mayor and CityCouncil ofBaltimoreMayor and City Council of BaltimoreVM PharmaVM PharmaKaren GriffinKaren GriffinLTS LohmannTherapie-SystemeAGLTS Lohmann Therapie-Systeme AGTerrence RonanTerrence RonanPurple StrategiesLLCPurple Strategies LLCSVC Pharma L.P.SVC Pharma L.P.William LoomisWilliam LoomisMundipharma, Ltd.Mundipharma, Ltd.

Solid line: documented. Amber dashed: reported. Grey dotted: hypothesis. One arrow: the relationship as stated; two arrows: reciprocal; no arrow: symmetric. A path between two parties does not transfer an allegation from one to the other.

every party and relationship in full, as text ↓

Information markers
  • A1 · Pleaded guilty in November 2020 to three federal conspiracy counts; sentenced in April 2026 — Purdue Pharma L.P.
  • A2 · Defendant in opioid suits by states and others; claims resolved through settlements and the 2025 bankruptcy plan — Purdue Pharma L.P.
  • A3 · Entered 2007 consent judgments with 26 states and D.C. over OxyContin promotion — Purdue Pharma L.P.
  • A4 · Filed for Chapter 11 on 15 September 2019; reorganisation plan effective 1 May 2026 — Purdue Pharma L.P.
  • A5 · Named with Purdue Pharma L.P. as a defendant in state opioid suits (2018–2019) — Purdue Pharma Inc.
  • A49 · Named as a defendant in the State of Rhode Island's opioid suit (complaint as amended in 2022) — Rhodes Pharmaceuticals L.P.
  • A50 · Named as a defendant in the State of Rhode Island's opioid suit (complaint as amended in 2022) — Rhodes Technologies
  • A6 · Pleaded guilty in May 2007 to felony misbranding of OxyContin — The Purdue Frederick Company, Inc.
  • A7 · Excluded from federal health care programs for 25 years from 2007 (HHS-OIG) — The Purdue Frederick Company, Inc.
  • A43 · Named as a defendant in the State of New York's opioid suit (2019) — The P.F. Laboratories, Inc.
  • A19 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Ilene Sackler Lefcourt
  • A20 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Beverly Sackler
  • A32 · Named as a director defendant in the Massachusetts and Connecticut suits (2019) — Cecil B. Pickett
  • A18 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — David A. Sackler
  • A27 · Party to the October 2020 civil settlement with the United States ($225 million), without admission of liability — David A. Sackler
  • A39 · Named as a defendant in the State of New York's opioid suit (2019) — Pharmaceutical Research Associates L.P.
  • A42 · Named as a defendant in the State of New York's opioid suit (2019) — PLP Associates Holdings L.P.
  • A41 · Named as a defendant in the State of New York's opioid suit (2019) — Beacon Company
  • A40 · Named as a defendant in the State of New York's opioid suit (2019) — Rosebay Medical Company L.P.
  • A21 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Theresa E. Sackler
  • A14 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Richard S. Sackler
  • A23 · Party to the October 2020 civil settlement with the United States ($225 million), without admission of liability — Richard S. Sackler
  • A28 · Found by the Bankruptcy Court in 2026 to have breached the 2025 settlement and confirmation order — Richard S. Sackler
  • A15 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Jonathan D. Sackler
  • A24 · Party to the October 2020 civil settlement with the United States ($225 million), without admission of liability — Jonathan D. Sackler
  • A16 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Mortimer D.A. Sackler
  • A25 · Party to the October 2020 civil settlement with the United States ($225 million), without admission of liability — Mortimer D.A. Sackler
  • A17 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Kathe A. Sackler
  • A26 · Party to the October 2020 civil settlement with the United States ($225 million), without admission of liability — Kathe A. Sackler
  • A30 · Named as a director defendant in the Massachusetts and Connecticut suits (2019) — F. Peter Boer
  • A31 · Named as a director defendant in the Massachusetts and Connecticut suits (2019) — Paulo Costa
  • A33 · Named as a director defendant in the Massachusetts and Connecticut suits (2019) — Ralph Snyderman
  • A37 · Named as a defendant in the Massachusetts suit and in other suits reported in 2019 — Craig Landau
  • A34 · Named as a director defendant in the Massachusetts and Connecticut suits (2019) — Judith C. Lewent
  • A36 · Named as a former-CEO defendant in the Massachusetts and Connecticut suits (2019) — Mark Timney
  • A35 · Named as a former-CEO defendant in the Massachusetts and Connecticut suits (2019) — John Stewart
  • A38 · Named as a defendant in the Massachusetts suit (2019) — Russell J. Gasdia
  • A22 · Named personally as a defendant in state opioid suits from 2019; claims stayed in the bankruptcy and settled under the 2025 plan for participating claimants — Marianna Sackler
  • A58 · Italian branch reported fined in a 2019 corruption case; the company denied wrongdoing — Mundipharma Italy
  • A51 · Named as a defendant in the State of Rhode Island's opioid suit (complaint as amended in 2022) — Rhodes Technologies Inc.
  • A8 · Pleaded guilty in May 2007 to misdemeanor misbranding as a responsible corporate officer — Michael Friedman
  • A9 · Excluded from federal health care programs by HHS-OIG; upheld by an administrative law judge in 2009 — Michael Friedman
  • A10 · Pleaded guilty in May 2007 to misdemeanor misbranding as a responsible corporate officer — Howard R. Udell
  • A11 · Excluded from federal health care programs by HHS-OIG; upheld by an administrative law judge in 2009 — Howard R. Udell
  • A12 · Pleaded guilty in May 2007 to misdemeanor misbranding as a responsible corporate officer — Paul D. Goldenheim
  • A13 · Excluded from federal health care programs by HHS-OIG; upheld by an administrative law judge in 2009 — Paul D. Goldenheim
  • A44 · Named in its own capacity as a distributor defendant in state opioid suits — McKesson Corporation
  • A45 · Named in its own capacity as a distributor defendant in state opioid suits — Cardinal Health, Inc.
  • A46 · Named in its own capacity as a distributor defendant in state opioid suits — AmerisourceBergen Drug Corporation
  • A47 · Named in its own capacity as a distributor defendant in state opioid suits — Rochester Drug Cooperative Inc.
  • A48 · Listed in 2024 by the New York Attorney General among companies paying opioid recoveries — AmerisourceBergen
  • A52 · Agreed in December 2024 to pay $650 million to resolve federal criminal and civil investigations of its Purdue work — McKinsey & Company, Inc.
  • A53 · February 2021 consent judgment with 47 states and others resolving investigations of its opioid work — McKinsey & Company, Inc.
  • A54 · Charged by Information in December 2024; resolved by a deferred prosecution agreement — McKinsey & Company, Inc. United States
  • A55 · Defendant in New York's February 2021 complaint, filed with a consent judgment — McKinsey & Company, Inc. United States
  • A56 · Charged in December 2024 with destroying records, according to the Justice Department — Martin E. Elling
  • A57 · $350 million agreement with state attorneys general in 2024 over its opioid marketing work — Publicis Health, LLC
  • A29 · Found by the Bankruptcy Court in 2026 to have breached the 2025 settlement and confirmation order — Lin Gao

Markers apply only to the named participant. They do not transfer allegations to connected parties.

Participants 205

Subject

Leadership

Group companies

Counterparties

Historical

Relationship register 410

chronology

  1. John Purdue Gray and George Frederick Bingham found the Purdue Frederick Company c-hist-origins
  2. Arthur, Mortimer and Raymond Sackler buy the Purdue Frederick Company c-hist-origins
  3. Richard, Jonathan and Kathe Sackler and Ilene Sackler Lefcourt begin their terms on the board of Purdue Pharma Inc. c-board-rsackler-director c-board-jsackler-director c-board-kathe-director c-board-ilene-director
  4. Purdue Pharma L.P. is formed as a Delaware limited partnership c-id-formation
  5. Ten Sackler family members are recorded as directors of Napp Pharmaceutical Group Limited from this date c-iac-napp-group-family
  6. The FDA approves OxyContin for marketing in the United States c-bus-irs-oxycontin-sales c-bus-principal-opioids
  7. Purdue launches OxyContin c-bus-principal-opioids
  8. FDA requires Purdue to drop a low-addiction-risk claim from the OxyContin label and add its strongest warning c-plea07-fda-2001-label
  9. The Purdue Pharma Inc. Political Action Committee is registered with the FEC c-bus-pac-fec
  10. Florida settles its investigation into Purdue for $500,000 c-lit-settle-florida-2002
  11. Purdue Pharma L.P. and Purdue Pharma Inc. are registered to do business in Florida c-id-florida-cards c-id-florida-2003
  12. West Virginia settles its suit against Purdue for $10 million c-lit-settle-west-virginia-2004
  13. The Purdue Pharma Company partnership is terminated; OxyContin sales are booked by Purdue Pharma L.P. c-hist-purdue-pharma-company c-hist-pfc-owner-2004
  14. Mississippi settles its investigation into Purdue for $250,000 c-lit-settle-mississippi-2006
  15. Purdue companies and Endo settle the OxyContin patent litigation with a consent judgment and licence c-bus-endo-2006 c-bus-endo-patents
  16. Twenty-six states and the District of Columbia settle with Purdue for $19.5 million under consent judgments c-plea07-state-settlement c-plea07-combined-total
  17. The Purdue Frederick Company pleads guilty to felony misbranding; three of its current and former executives plead guilty to misdemeanours c-plea07-pfc-plea c-plea07-executive-pleas
  18. David Sackler emails Richard and Jonathan Sackler and an adviser about the family's liability, as the District Court recounted c-fam-2007-email-counsel
  19. Jonathan, Kathe and Mortimer D.A. Sackler end their officer titles at Purdue Pharma Inc. and Purdue Pharma L.P. c-board-family-officers-2007
  20. John Stewart becomes chief executive officer of Purdue Pharma L.P. and Purdue Pharma Inc. c-exec-stewart-ceo
  21. Judge James P. Jones approves The Purdue Frederick Company's plea agreement c-plea07-plea-approval
  22. A family financial adviser warns Jonathan Sackler of uncapped liabilities, according to the District Court c-fam-2007-advisor-memo
  23. Around 1 January, Rhodes Tech leaves Purdue Pharma L.P. for another Sackler ownership chain, the debtors state c-bus-rhodes-history
  24. Mortimer D.A. Sackler writes that the family is too exposed to pharmaceuticals, as Connecticut's complaint quotes c-fam-mda-2008-email
  25. Peter Boer becomes a director of Purdue Pharma Inc. c-board-boer
  26. Purdue Pharmaceutical Products L.P. and Infinity Pharmaceuticals form a strategic alliance c-bus-infinity-alliance c-bus-infinity-investment
  27. Administrative law judge upholds the 15-year HHS-OIG exclusions of the three former Purdue Frederick executives c-plea07-executive-exclusions
  28. Purdue Pharma L.P. buys Series E preferred stock and warrants of Novelos Therapeutics for $10 million c-bus-novelos-purchase
  29. WIPO panel orders four OxyContin domain names transferred to Purdue Pharma L.P. c-bus-oxycontin-trademarks
  30. Monitoring period under Purdue Pharma L.P.'s 2007 Corporate Integrity Agreement expires c-plea07-cia
  31. Purdue executives sign the consulting contract for the OxyContin sales assessment later called E2E c-cons-addendum-contract c-cons-consulting-company-identity
  32. Mark Timney becomes chief executive officer of Purdue Pharma L.P. and Purdue Pharma Inc. c-exec-timney-ceo
  33. KBR announces a contract to build Purdue Pharma Manufacturing L.P.'s Durham plant c-bus-durham-kbr
  34. Purdue agrees to pay Kentucky $24 million to settle the state’s 2007 suit c-lit-settle-kentucky
  35. New York ends its investigation of Purdue Pharma L.P. by an assurance of discontinuance and a $75,000 penalty c-lit-settle-new-york-2015
  36. Celldex Therapeutics completes its merger with Kolltan Pharmaceuticals c-dist-celldex-kolltan
  37. Federal opioid cases against Purdue and other defendants are sent to MDL-2804 in Ohio c-lit-second-wave-mdl
  38. Cash distributions to the Sackler families end and Purdue Pharma L.P. lends $313 million to its parent, the debtors state c-dist-cessation
  39. Craig Landau is appointed President and CEO of Purdue Pharma L.P. as Mark Timney leaves c-board-landau-network-board c-exec-landau-ceo c-exec-timney-ceo
  40. At Craig Landau's direction Purdue stops using sales representatives to promote opioids to prescribers c-exec-landau-promotion-stop
  41. Companies House records seven family directors leaving Napp Pharmaceutical Group and five leaving Napp Holdings c-iac-napp-group-family c-iac-napp-holdings-family
  42. Purdue Pharma L.P. names Steve Miller board chairman and Marc Kesselman general counsel c-board-miller-appointed c-exec-kesselman-appointed
  43. Richard Sackler leaves the board of Purdue Pharma Inc. c-board-rsackler-director
  44. The New York Attorney General sues Purdue Pharma over the marketing of OxyContin c-lit-new-york
  45. Purdue entities agree to pay Assertio $62 million to settle a patent case c-bus-assertio-2018
  46. Cornice Fiduciary Management LLC succeeds Leslie J. Schreyer as trustee of a 1989 trust for the issue of Jonathan D. Sackler c-own-cornice-succession
  47. Two Mundipharma managers accept plea bargains in an Italian corruption case, according to a press report c-iac-mundipharma-italy-case
  48. Mortimer D.A. Sackler, the last family director, leaves the board of Purdue Pharma Inc. c-board-mdas-director c-board-sackler-exit
  49. The FDA's approval of Adlon Therapeutics' Adhansia XR is reported c-bus-adlon-adhansia
  50. Purdue settles Oklahoma’s opioid suit for $270 million c-lit-settle-oklahoma-2019 c-lit-oklahoma-family-contribution
  51. New York amends its complaint to add claims against eight family members and Sackler entities c-lit-new-york
  52. Rhodes Pharma and Rhodes Tech are contributed to Purdue Pharma L.P., the debtors state c-bus-rhodes-history
  53. Connecticut amends its complaint against Purdue, eight family members, five directors, John Stewart and Mark Timney c-lit-connecticut
  54. Purdue Pharma Inc.'s shareholders create a Transaction Committee closed to Sackler family members c-board-transaction-committee
  55. Maryland’s Consumer Protection Division opens an administrative proceeding against Purdue c-lit-maryland
  56. John S. Dubel and Michael Cola take At-Large Director seats on the board of Purdue Pharma Inc. c-board-2025-directors
  57. The Transaction Committee is renamed the Special Committee and given authority over litigation with the Sackler Families c-board-special-committee-2019
  58. A New York court seeks documents from Banela Corporation in the British Virgin Islands c-lit-ny-letter-rogatory
  59. Purdue Pharma L.P. and 23 affiliates file for Chapter 11; no Sackler family member or family entity files c-ch11-petition c-ch11-sacklers-not-debtors
  60. The debtors' ownership statement names PRA as sole owner of Purdue Pharma L.P. and Banela, Linarite and Perthlite as owners of Purdue Pharma Inc. c-own-pra-pplp c-own-ppi-shareholders
  61. Notice of the bankruptcy stay is filed in the Massachusetts case c-lit-massachusetts
  62. The U.S. Trustee appoints the Official Committee of Unsecured Creditors in the Purdue case c-ch11-ucc
  63. Cedar Cliff Fiduciary Management Inc. is first registered as a Wyoming corporation c-own-cedar-cliff-registry
  64. The Bankruptcy Court halts litigation against Purdue and non-debtor related parties, including Sackler family members c-ch11-injunction
  65. Purdue Pharma Inc.'s shareholders delegate the power to appoint and remove the chairman and at-large directors to its general counsel c-board-letter-agreement
  66. The Bankruptcy Court's preliminary injunction order protects the debtors and the named non-debtor Related Parties c-ch11-injunction c-rel-related-parties
  67. The debtors file the 1A Report: about $10.347 billion of net cash distributions to or for Sackler family members and entities, 2008–2019 c-dist-1a-report
  68. The Ontario Superior Court of Justice extends the recognised stay to the Related Parties in Canada c-ch11-canada-recognition
  69. The Bankruptcy Court appoints Layn Phillips and Kenneth Feinberg as co-mediators c-ch11-mediation
  70. The debtors file the 1B Report on non-cash transfers and dealings with Sackler entities c-dist-1b-bates-white
  71. Jonathan Sackler dies, according to a court filing cited in the press; his estate later signs the 2020 settlement c-fam-jonathan-death
  72. The extended deadline for proofs of claim against the Purdue debtors expires c-ch11-bar-date
  73. The United States files a civil proof of claim in Purdue's bankruptcy estimating single damages of $2.8 billion or more c-plea20-proof-of-claim
  74. The Bankruptcy Court approves the sale of Rhodes Tech's Coventry plant to Noramco Coventry LLC c-bus-coventry-sale
  75. DOJ announces Purdue Pharma L.P.'s agreement to plead guilty and a separate $225 million civil settlement with five Sackler family members c-plea20-global-resolution c-plea20-sackler-settlement
  76. Information filed; Purdue Pharma L.P. pleads guilty to three federal conspiracy counts c-plea20-information c-plea20-plea
  77. The debtors file their first plan, built on the Sackler families' $4.275 billion contribution c-ch11-sackler-agreement c-ch11-plan-path
  78. Judge Drain confirms the Twelfth Amended plan, including releases of claims against the Sackler family c-ch11-plan-path
  79. The District Court vacates the confirmation order, holding nonconsensual third-party releases unauthorised c-rel-dc-holding
  80. The Bankruptcy Court approves the term sheet raising the Sackler contribution; eight states and D.C. drop objections c-ch11-nine-settlement
  81. The Second Circuit reverses the District Court and reinstates confirmation of the plan c-rel-ca2-decision
  82. The sale of Avrio Health's assets to an Arcadia Consumer Healthcare subsidiary closes c-bus-avrio-sale
  83. Attorneys general announce a $350 million agreement with Publicis Health c-cons-publicis-resolution
  84. The Supreme Court holds in Harrington v. Purdue Pharma L.P. that the code does not authorise nonconsensual releases of claims against non-debtors c-rel-scotus-holding
  85. The Bankruptcy Court grants the creditors' committee sole standing to pursue the estates' claims c-ch11-ucc-standing
  86. Mediators report agreements in principle with all but one Sackler family group, the debtors and creditor groups c-rel-2024-mediation
  87. The District Court affirms the 2024 injunction extensions on the State of Maryland's appeal c-rel-maryland-appeal
  88. McKinsey agrees to a $650 million resolution with a deferred prosecution agreement over charges against its U.S. subsidiary c-cons-mck-2024-resolution c-cons-mck-information c-cons-elling-charge
  89. Purdue's debtors file the Thirteenth Amended Chapter 11 plan after the Supreme Court remand c-plan25-thirteenth-plan
  90. Stipulation dismisses Richard Sackler's Wyoming trust suit and binds him and Lin Gao not to interfere with the settlement c-enf-wyoming-litigation
  91. Bankruptcy Court confirms the Eighteenth Amended plan with opt-in third-party releases c-plan25-confirmation c-plan25-releases
  92. Purdue Pharma L.P. is sentenced to a $3.544 billion criminal fine and $2 billion forfeiture c-plea20-sentence
  93. Plan takes effect: Purdue ceases operations and Knoa Pharma LLC begins operating its business c-plan25-effective c-plan25-knoa-launch
  94. Bankruptcy Court grants the Side B trustees' motion to enforce the settlement against Richard Sackler and Lin Gao c-enf-side-b-motion c-enf-breach-ruling
  95. Florida records cancellation of Purdue Pharma L.P. and withdrawal of Purdue Pharma Inc. c-id-florida-cards
  96. Written ruling finds Richard Sackler and Lin Gao breached the confirmation order, settlement agreement and stipulation c-enf-breach-ruling

cite this dossier

DossierTwist, “Purdue Pharma L.P.: owners, OxyContin cases and bankruptcy”, dt.034, 2 November 2026, https://dossiertwist.com/dossiers/purdue-pharma/

Free to read, cite and republish with credit under CC BY 4.0: credit “DossierTwist” and link to the dossier.

Data: JSON, CSV and the network graph.

share

We listen to all sides: responses are shown next to the claims they answer. To send a correction or a reply, write to dossiertwist@proton.me.